Skip to main content
Clinical Trials/NCT06483399
NCT06483399
Completed
Not Applicable

Influence of Nutritional Risk Indexes and Inflammatory Indicators on Postoperative Complications and Prognosis of Epithelial Ovarian Cancer and Construction of Prediction Models

Qinglei Gao0 sites1,108 target enrollmentJanuary 1, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Epithelial Ovarian Cancer
Sponsor
Qinglei Gao
Enrollment
1108
Primary Endpoint
Progression-free survival
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this observational study is to explore the influence and predictive significance of nutritional risk indicators and inflammatory indicators on postoperative complications and prognosis of patients with epithelial ovarian cancer (EOC). The main question it aims to answer is:

Can preoperative nutritional risk and inflammatory indexes predict postoperative complications? Do preoperative nutritional risk and inflammatory indexes better predict the prognosis of patients with epithelial ovarian cancer? Which index is the best predictor of postoperative complications or prognosis for patients?

Registry
clinicaltrials.gov
Start Date
January 1, 2012
End Date
February 28, 2023
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Qinglei Gao
Responsible Party
Sponsor Investigator
Principal Investigator

Qinglei Gao

Professor

Tongji Hospital

Eligibility Criteria

Inclusion Criteria

  • histologically confirmed primary epithelial ovarian, peritoneal, and fallopian tube cancers.
  • patients received comprehensive staged surgery or debulking surgery.
  • available data of laboratory examination within 7 days before the surgery.

Exclusion Criteria

  • borderline ovarian tumor.
  • receipt of neoadjuvant chemotherapy.
  • presence of other conditions influencing laboratory data, like hepatitis, kidney disease, autoimmune diseases, infectious diseases, blood disease, etc.
  • concurrent cancer in other organs.
  • absence of surgery or biopsy only.
  • multiple staged surgeries.

Outcomes

Primary Outcomes

Progression-free survival

Time Frame: From the date the patient diagnosed with primary ovarian, fallopian tube, or peritoneal cancer to the date of disease progression or death or last follow-up, whichever occurred first, assessed up to 100 months.

Interval between first diagnosis and first recurrence, death, or last follow-up

Postoperative Complications

Time Frame: Within 30 days after surgery

Surgical complications within 30 days after comprehensive staging or cytoreductive surgery recorded according to the Clavien-Dindo grading system

Overall survival

Time Frame: From the date the patient diagnosed with primary ovarian, fallopian tube, or peritoneal cancer to the date of death or last follow-up, whichever occurred first, assessed up to 100 months.

Interval between first diagnosis and death, or last follow-up

Similar Trials